Literature DB >> 17728694

National vaccination coverage among adolescents aged 13-17 years--United States, 2006.

.   

Abstract

Before 2005, vaccines were administered during adolescence to "catch up" children with vaccinations not received at a younger age, with the exception of the tetanus and diphtheria (Td) booster. However, since 2005, three new vaccines specifically for older children have been licensed and recommended in the United States: meningococcal conjugate vaccine (MCV4) for those aged 11-12 years and 15 years; tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine for those aged 11-12 years (or at ages 13-18 years if not received at ages 11-12 years); and human papillomavirus (HPV) vaccine for girls aged 11-12 years (or at ages 13-18 years if not received at 11-12 years). Since 1996, the Advisory Committee on Immunization Practices (ACIP) and professional organizations, including the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American Medical Association (AMA), have recommended a health-care visit at ages 11-12 years for receipt of recommended vaccinations. In addition, a Healthy People 2010 objective (14-27) is to achieve > or =90% vaccination coverage among adolescents aged 13-15 years for certain vaccines. In 2006, for the first time, the National Immunization Survey (NIS) collected provider-reported vaccination information for adolescents aged 13-17 years (NIS-Teen). This report describes the results of that survey, which indicated that the Healthy People 2010 target has not been met for any of the vaccines analyzed. HPV vaccination coverage is not included in this report because NIS-Teen was conducted before HPV vaccination recommendations were published in March 2007. Routine health-care visits for adolescents should be encouraged, with emphasis on a visit at ages 11-12 years, and providers should continue to assess the need for vaccinations at every opportunity. NIS-Teen will be conducted annually to monitor coverage with recommended vaccines during ages 11-17 years and to identify groups with lower coverage.

Entities:  

Mesh:

Year:  2007        PMID: 17728694

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  14 in total

1.  Hepatitis B vaccination among adolescents 13-17 years, United States, 2006-2012.

Authors:  Peng-jun Lu; David Yankey; Jenny Jeyarajah; Alissa O'Halloran; Laurie Elam-Evans; Stacie M Greby; James A Singleton; Trudy V Murphy
Journal:  Vaccine       Date:  2015-02-25       Impact factor: 3.641

2.  Determining accurate vaccination coverage rates for adolescents: the National Immunization Survey-Teen 2006.

Authors:  Nidhi Jain; James A Singleton; Margrethe Montgomery; Benjamin Skalland
Journal:  Public Health Rep       Date:  2009 Sep-Oct       Impact factor: 2.792

3.  Highlights of historical events leading to national surveillance of vaccination coverage in the United States.

Authors:  Philip J Smith; David Wood; Paul M Darden
Journal:  Public Health Rep       Date:  2011 Jul-Aug       Impact factor: 2.792

4.  Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults.

Authors:  Natalie L McCarthy; Julianne Gee; Lakshmi Sukumaran; Eric Weintraub; Jonathan Duffy; Elyse O Kharbanda; Roger Baxter; Stephanie Irving; Jennifer King; Matthew F Daley; Rulin Hechter; Michael M McNeil
Journal:  Pediatrics       Date:  2016-02-01       Impact factor: 7.124

5.  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark
Journal:  MMWR Recomm Rep       Date:  2018-04-27

6.  Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate.

Authors:  Amanda F Dempsey; David Mendez
Journal:  J Adolesc Health       Date:  2010-02-11       Impact factor: 5.012

7.  Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005.

Authors:  Lee H Harrison; Kathleen A Shutt; Susanna E Schmink; Jane W Marsh; Brian H Harcourt; Xin Wang; Anne M Whitney; David S Stephens; Amanda A Cohn; Nancy E Messonnier; Leonard W Mayer
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

8.  Health and economic implications of HPV vaccination in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

9.  Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: demand, supply and seasonality.

Authors:  Suchita A Lorick; Daniel Fishbein; Eric Weintraub; Pascale M Wortley; Grace M Lee; Fangjun Zhou; Robert Davis
Journal:  BMC Infect Dis       Date:  2009-11-03       Impact factor: 3.090

10.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  BMJ       Date:  2009-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.